Status:
TERMINATED
TARGET GCAT Registry
Lead Sponsor:
University of Leeds
Collaborating Sponsors:
University of Oxford
Hoffmann-La Roche
Conditions:
Giant Cell Arteritis
Eligibility:
All Genders
50+ years
Brief Summary
A longitudinal post-marketing surveillance registry nested within the UK GCA Consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of GCA in...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patient must have a diagnosis of GCA and be eligible for the UK GCA Consortium study
- Willing and able to consent
- Have refractory or relapsing GCA as defined by the NHS England commissioning statement for tocilizumab.
- Require treatment escalation
Exclusion
Key Trial Info
Start Date :
May 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04049071
Start Date
May 13 2019
End Date
June 30 2020
Last Update
May 12 2021
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust
Birmingham, United Kingdom
2
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
3
Royal Derby Hospital, University Hospital of Derby and Burton NHS Foundation Trust
Derby, United Kingdom
4
Ninewells Hospital and Medical School, NHS Tayside
Dundee, United Kingdom